NASDAQ:DERM - Dermira Stock Price, Forecast & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dermira.

Dermira Inc (NASDAQ:DERM) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.40) by $0.34. The biopharmaceutical company earned $11.53 million during the quarter, compared to analyst estimates of $11.07 million. Dermira had a negative net margin of 256.08% and a negative return on equity of 583.07%. View Dermira's earnings history.

7 Wall Street analysts have issued 12-month price targets for Dermira's shares. Their forecasts range from $14.00 to $25.00. On average, they expect Dermira's stock price to reach $18.55 in the next twelve months. This suggests that the stock has a possible downside of 1.1%. View analysts' price targets for Dermira.

Media headlines about DERM stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dermira earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutDermira.

Some companies that are related to Dermira include United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Evotec (EVTCY), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Emergent Biosolutions (EBS), FibroGen (FGEN), PTC Therapeutics (PTCT), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB) and Agios Pharmaceuticals (AGIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), AT&T (T), Novavax (NVAX), Exelixis (EXEL), Bristol-Myers Squibb (BMY), ImmunoGen (IMGN), Karyopharm Therapeutics (KPTI) and Sangamo Therapeutics (SGMO).

Dermira trades on the NASDAQ under the ticker symbol "DERM."

Dermira's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Fred Alger Management LLC (5.60%), Oracle Investment Management Inc. (4.64%), Bank of America Corp DE (3.70%), State Street Corp (1.80%), Broadfin Capital LLC (1.64%) and Earnest Partners LLC (1.48%). Company insiders that own Dermira stock include Eagle Acquisition Corp Bald, Eugene A Bauer, Matthew K Fust and Thomas G Wiggans. View institutional ownership trends for Dermira.

DERM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Credit Suisse AG, Citigroup Inc., Fred Alger Management LLC, Renaissance Technologies LLC, Sofinnova Investments Inc., Panagora Asset Management Inc., and Partner Investment Management L.P.. Company insiders that have sold Dermira company stock in the last year include Eugene A Bauer, and Matthew K Fust. View insider buying and selling activity for Dermira.

DERM stock was bought by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Jacobs Levy Equity Management Inc., Broadfin Capital LLC, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Earnest Partners LLC, Alliancebernstein L.P., and EAM Global Investors LLC. Company insiders that have bought Dermira stock in the last two years include Eagle Acquisition Corp Bald, and Thomas G Wiggans. View insider buying and selling activity for Dermira.

One share of DERM stock can currently be purchased for approximately $18.75.

Dermira has a market capitalization of $1.02 billion and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis. Dermira employs 333 workers across the globe. View additional information about Dermira.

The official website for Dermira is http://www.dermira.com/.

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]